ARCHIVES

Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance

This article is from The Cancer Letter archive.

Vol. 22 No. 48 | December 13, 1996

Download PDF Visit The Full Archive

Related Articles

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005

“What Is Good For NCI Is Good For NIH,” Broder Says In Address

January 13, 1995

DC E Bard Approves Health Plan Study Recompetition, New Acrylonitrile Contract

March 16, 1984

Prospects Fading for Funding More CCOPsIn FY ’83; Return to Groups Of Money From Satellites Going To New Programs

July 29, 1983

NCI-Approved Clinical Trials Listed For Month Of March

April 27, 2001

Scatter Radiation from Mammography Presents No Increased Cancer Risk

December 28, 2012